Skip to content

Effect of Jiangya Tongmai Formula on endothelial function and inflammation in patients with H-type hypertension complicated with carotid atherosclerosis

Effect of Jiangya Tongmai Formula on endothelial function and inflammation in patients with H-type hypertension complicated with carotid atherosclerosis

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300070509
Enrollment
Unknown
Registered
2023-04-14
Start date
2023-04-15
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H-type hypertension

Interventions

treatment group:Jiangyitongmai formula
Control group:Placebo

Sponsors

Xiyuan Hospital, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) It meets the diagnostic criteria for H-type hypertension, and the blood pressure level is grade-1 and grade-2; (2) It meets the diagnostic criteria for Tanyuhujie sysdrome; (3) It meets the diagnostic criteria for carotid atherosclerosis, carotid artery ultrasound indicated that the thickness of carotid intima-media was =1.0mm; (4) Aged 30-75 years old; ? Volunteer to participate in the experiment and sign the informed consent.

Exclusion criteria

Exclusion criteria: ? Can not cooperate; ? Secondary hypertension; (3) Patients who ccombined with severe cardiovascular and cerebrovascular diseases, such as acute myocardial infarction, acute heart failure, stroke, unstable angina, active myocarditis or pericarditis; Patients who had received PCI or CABG within 90 days prior to inclusion or expected to receive PCI or CABG within 90 days. (4) Patients who received infectious diseases; ? Patients who had severe impairment of liver and kidney function (serum ALT 3 times higher than the normal value; Cr > 1.5 times the upper limit of normal reference value). ? Patients who had serious hematologic disease, serious mental illness, connective tissue disease or malignant tumor; ? Possible or confirmed allergy to the test ingredient; ? if the duration of taking statin is less than 6 months before joining the group; (9) Women during the period of pregnancy, planned pregnancy, or lactation; (10) Patients who is currently participating in other studies.

Design outcomes

Primary

MeasureTime frame
Endothelium function and inflammatory factor;

Secondary

MeasureTime frame
Blood pressure variability;Serum homocysteine;Serum lipid;Carotid artery ultrasound;TCM syndrome score;

Countries

China

Contacts

Public ContactDuan Wenhui

Xiyuan Hospital, China Academy of Chinese Medical Sciences

duanwh168@126.com+86 13051591212

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026